MIRM•benzinga•
Mirum Pharmaceuticals Projects $336M Sales Exceed 2024 Guidance; 2025 Sales Forecast $420M-$435M; VISTAS Study Enrollment For Volixibat In Primary Sclerosing Cholangitis Completing H2 2025, Topline Data Expected 2026
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 13, 2025 by benzinga